Chad J. Swanson
Eisai
36 Papers
53 Citations
Chad J. Swanson is an academic researcher from Eisai. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 16 publications.
Chat about Author
Papers
Lecanemab in Early Alzheimer's Disease.
Christopher H. van Dyck,Chad J. Swanson,P. Aisen,Randall J. Bateman,Christopher Chen,Michelle Gee,Michio Kanekiyo,David JianJun Li,Larisa Reyderman,Sharon Cohen,Lutz Froelich,Sadao Katayama,Marwan N. Sabbagh,Bruno Vellas,David Watson,Shobha Dhadda,Michael C Irizarry,Lynn D. Kramer,Takeshi Iwatsubo +18 more
TL;DR: Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils, is being tested in persons with early Alzheimer's disease as mentioned in this paper .
1.3K
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Chad J. Swanson,Yong Zhang,Shobha Dhadda,Jinping Wang,June Kaplow,Robert Lai,Lars Lannfelt,Heather Bradley,Martin Rabe,Akihiko Koyama,Larisa Reyderman,Donald A. Berry,Scott M. Berry,Robert Gordon,Lynn D. Kramer,Jeffrey L. Cummings +15 more
TL;DR: Prespecified 18-month Bayesian and frequentist analyses demonstrated reduction in brain amyloid accompanied by a consistent reduction of clinical decline across several clinical and biomarker endpoints, and a phase 3 study (Clarity AD) in early Alzheimer’s disease is underway.
Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody
Veronika Logovinsky,Andrew Satlin,Robert Lai,Chad J. Swanson,June Kaplow,Gunilla Osswald,Hans Basun,Lars Lannfelt +7 more
TL;DR: The first clinical study with BAN2401, a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils, found it well-tolerated across all doses and guided the selection of dose and dose regimens in the ongoing phase 2b study.
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
Eric McDade,Jeffrey L. Cummings,Shobha Dhadda,Chad J. Swanson,Larisa Reyderman,Michio Kanekiyo,Akihiko Koyama,Michael C Irizarry,Lynn D. Kramer,Randall J. Bateman +9 more
TL;DR: Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD as mentioned in this paper .
The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease
Michael S. Rafii,Reisa A. Sperling,Michael C. Donohue,Jin Zhou,Claire Roberts,Michael C Irizarry,Shobha Dhadda,Gopalan Sethuraman,Lynn D. Kramer,Chad J. Swanson,David JianJun Li,Stephen Krause,Robert A. Rissman,Sarah Walter,Rema Raman,Keith A. Johnson,Paul S. Aisen +16 more
TL;DR: The AHEAD 3-45 Study will test whether with lecanemab (BAN2401) can slow the accumulation of tau and prevent the cognitive decline associated with AD during its preclinical stage, and is the first secondary prevention trial to employ plasma-based biomarkers to accelerate the screening process and potentially substantially reduce the number of screening PET scans.
114